PMID- 28508457
OWN - NLM
STAT- MEDLINE
DCOM- 20180716
LR  - 20210109
IS  - 1742-1241 (Electronic)
IS  - 1368-5031 (Print)
IS  - 1368-5031 (Linking)
VI  - 71
IP  - 5
DP  - 2017 May
TI  - Effects of canagliflozin on cardiovascular risk factors in patients with type 2 
      diabetes mellitus.
LID - 10.1111/ijcp.12948 [doi]
LID - e12948
AB  - BACKGROUND AND AIMS: Cardiovascular disease is the most common cause of morbidity 
      and mortality among people with type 2 diabetes mellitus (T2DM). The main 
      contributors to cardiovascular risk in T2DM are chronic hyperglycaemia, reduced 
      insulin sensitivity, hypertension and dyslipidaemia. Other cardiovascular risk 
      factors include obesity and visceral adiposity, increased arterial stiffness and 
      renal dysfunction. Results from clinical trials, including a long-term 
      cardiovascular outcome study, have shown that sodium glucose co-transporter 2 
      (SGLT2) inhibitors can provide multiple cardiometabolic benefits beyond glycaemic 
      control including inducing mild osmotic diuresis, natriuresis and weight loss. 
      This review article describes the effects of canagliflozin on cardiovascular risk 
      factors based on results from its clinical development programme. METHODS: This 
      review is based on structured searches to identify literature related to the 
      effects of canagliflozin on cardiovascular risk factors in patients with T2DM. 
      DISCUSSION AND CONCLUSIONS: Canagliflozin treatment has been shown to provide 
      glycaemic improvements as well as reductions in blood pressure and body weight 
      across a broad range of patients with T2DM, including those with elevated 
      cardiovascular risk. Other observed effects of canagliflozin that may contribute 
      to improved cardiometabolic outcomes include reduction in uric acid levels, 
      decreased albuminuria and increases in serum magnesium. Results of ongoing 
      long-term cardiovascular outcomes studies of canagliflozin are expected to 
      provide additional evidence on the cardiometabolic effects of canagliflozin 
      treatment.
CI  - (c) 2017 The Authors International Journal of Clinical Practice Published by John 
      Wiley & Sons Ltd.
FAU - Budoff, Matthew J
AU  - Budoff MJ
AUID- ORCID: 0000-0002-9616-1946
AD  - Division of Cardiology, Los Angeles Biomedical Research Institute, Torrance, CA, 
      USA.
FAU - Wilding, John P H
AU  - Wilding JPH
AD  - Obesity and Endocrinology Clinical Research, Institute of Ageing and Chronic 
      Disease, University of Liverpool, Liverpool, UK.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - India
TA  - Int J Clin Pract
JT  - International journal of clinical practice
JID - 9712381
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - 0SAC974Z85 (Canagliflozin)
SB  - IM
MH  - Canagliflozin/*therapeutic use
MH  - Cardiovascular Diseases/etiology/*prevention & control
MH  - Diabetes Mellitus, Type 2/complications/*drug therapy
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Risk Factors
MH  - Sodium-Glucose Transporter 2 Inhibitors
MH  - Treatment Outcome
PMC - PMC5488174
EDAT- 2017/05/17 06:00
MHDA- 2018/07/17 06:00
PMCR- 2017/06/28
CRDT- 2017/05/17 06:00
PHST- 2016/12/16 00:00 [received]
PHST- 2017/03/12 00:00 [accepted]
PHST- 2017/05/17 06:00 [entrez]
PHST- 2017/05/17 06:00 [pubmed]
PHST- 2018/07/17 06:00 [medline]
PHST- 2017/06/28 00:00 [pmc-release]
AID - IJCP12948 [pii]
AID - 10.1111/ijcp.12948 [doi]
PST - ppublish
SO  - Int J Clin Pract. 2017 May;71(5):e12948. doi: 10.1111/ijcp.12948.